Stay updated on Tirzepatide in HFpEF & Obesity Clinical Trial
Sign up to get notified when there's something new on the Tirzepatide in HFpEF & Obesity Clinical Trial page.

Latest updates to the Tirzepatide in HFpEF & Obesity Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check38 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed study information regarding Tirzepatide's efficacy and safety in heart failure patients with obesity, while a new identifier related to Eli Lilly and Company has been added.SummaryDifference10%
- Check46 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check53 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check82 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check103 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Tirzepatide in HFpEF & Obesity Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tirzepatide in HFpEF & Obesity Clinical Trial page.